非酒精性脂肪性肝炎治疗靶点及药物研发进展  

Progress in the development of therapeutic targets and drugs for non-alcoholic steatohepatitis

作　　者：傅宇洁 陈曦慧 刘珉宇 FU Yujie;CHEN Xihui;LIU Minyu(State Key Laboratory of New Drug and Pharmaceutical Process,Shanghai Institute of Pharmaceutical Industry,China State Institute of Pharmaceutical Industry,Shanghai 200437,China;Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation,Shanghai Institute of Pharmaceutical Industry,China State Institute of Pharmaceutical Industry,Shanghai 200437,China)

机构地区：[1]中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海200437 [2]上海市生物物质成药性评价技术服务平台,上海200437

出　　处：《世界临床药物》2025年第2期123-129,142,共8页World Clinical Drug

摘　　要：非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)作为一种慢性代谢性疾病,与肥胖、2型糖尿病及高脂血症等代谢综合征密切相关。其发病机制涉及遗传、环境及生活方式等多种因素,特别是代谢紊乱作为核心驱动力,通过氧化应激、内质网应激及炎症通路激活等多种途径促进疾病进展。针对NASH的治疗,已识别出多个潜在的治疗靶点,如代谢调节、炎症通路阻断及抗纤维化等。NASH还可能进展为肝硬化、肝癌等严重疾病,对人类健康构成重大威胁。此外,NASH还常伴其他代谢性疾病,形成恶性循环,进一步加剧治疗难度和患者负担。该文旨在全面综述NASH的发病机制、治疗靶点及药物研究进展,并探讨其对人类的危害,为未来的研究和临床实践提供参考。Non-alcoholic steatohepatitis(NASH),as a chronic metabolic disease,is closely related to obesity,diabetes mellitus type 2,hyperlipidemia and other metabolic syndromes.Its pathogenesis involves multiple factors such as genetics,environment and lifestyle,especially metabolic disorders as the core driving force,which promote disease progression through oxidative stress,endoplasmic reticulum stress and inflammatory pathway activation.For the treatment of NASH,multiple potential therapeutic targets have been identified,such as metabolic regulation,blocking of inflammatory pathways,and anti-fibrosis.NASH may also progress to severe diseases such as cirrhosis and liver cancer,which poses a major threat to human health.In addition,NASH is often accompanied by other metabolic diseases,forming a vicious cycle that further increases the difficulty of treatment and the burden on patients.This article aims to comprehensively review the pathogenesis,therapeutic targets and drug research progress of NASH,and discuss its harm to humans,so as to provide reference for future research and clinical practice.

关 键 词：非酒精性脂肪性肝炎 代谢 治疗靶点 药物研发进展 

分 类 号：R575.5[医药卫生—消化系统]